Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Cash from Operations (2016 - 2025)

Kiora Pharmaceuticals' Cash from Operations history spans 11 years, with the latest figure at 2180455.0 for Q4 2025.

  • For Q4 2025, Cash from Operations rose 3.19% year-over-year to 2180455.0; the TTM value through Dec 2025 reached 9961176.0, down 216.38%, while the annual FY2025 figure was 9961176.0, 216.38% down from the prior year.
  • Cash from Operations reached 2180455.0 in Q4 2025 per KPRX's latest filing, down from 1273088.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 13624855.0 in Q1 2024 to a low of 3803434.0 in Q2 2025.
  • Average Cash from Operations over 5 years is 1439222.82, with a median of 2570051.0 recorded in 2021.
  • Peak YoY movement for Cash from Operations: skyrocketed 543.87% in 2024, then tumbled 238.37% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 2919668.0 in 2021, then grew by 2.99% to 2832386.0 in 2022, then increased by 8.86% to 2581341.0 in 2023, then increased by 12.74% to 2252358.0 in 2024, then increased by 3.19% to 2180455.0 in 2025.
  • Per Business Quant, the three most recent readings for KPRX's Cash from Operations are 2180455.0 (Q4 2025), 1273088.0 (Q3 2025), and 3803434.0 (Q2 2025).